Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Disc Medicine Inc IRON
$77.00
▼ -2.79%
($-2.21)
🔥 High Short Interest
🎢 High Beta
📅 Earnings This Week
Open
$78.42
Prev Close
$79.21
Day Range
$75.01 – $79.32
52W Range
$40.00 – $99.50
Market Cap
$2.94B
Beta
0.97
EPS (TTM)
$-6.61
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-08-12 |
| Shares Out. | 38,200,000 |
| Website | discmedicine.com/ ↗ |
| Phone | 16176749274 |
| Employees | 155 |
| Net Income | -$63.5M |
| Free Cash Flow | -$201.3M |
| Total Assets | $750.2M |
| Total Liabilities | $61.8M |
| Equity | $688.4M |
About Disc Medicine Inc
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Disc Medicine Inc is a publicly traded company under the ticker symbol IRON on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)